Literature DB >> 16452357

Vaccine adverse event reporting system reporting source: a possible source of bias in longitudinal studies.

Michael J Goodman1, James Nordin.   

Abstract

OBJECTIVE: The US Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system to which anyone can report an event. Publicity related to potential adverse events may change reporting patterns. The objective of this paper is to show how litigation-related reports have influenced the trends in possible adverse event reports to VAERS.
METHODS: The VAERS public-use data files were downloaded in July 2004 and translated into identical SAS data sets for analysis. Cases that were related to litigation were identified using a word search algorithm. All cases for the most frequently reported symptoms in litigation (overdose, neuropathy, autism, "mental retardation," arthralgia, and "speech disorder") were reviewed.
RESULTS: In recent years, most case reports to VAERS that were related to overdose, neuropathy, and thimerosal were related to litigation. Many cases that were related to autism and mental retardation were as well.
CONCLUSIONS: This review shows a previously undisclosed rise in the number of reports to the VAERS related to pending litigation for vaccine injury. The implications of this for understanding longitudinal reporting patterns are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452357     DOI: 10.1542/peds.2004-2687

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  2 in total

1.  Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.

Authors:  James R Rogers; Ameet Sarpatwari; Rishi J Desai; Justin M Bohn; Nazleen F Khan; Aaron S Kesselheim; Michael A Fischer; Joshua J Gagne; John G Connolly
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

Review 2.  Do GLP-1-based therapies increase cancer risk?

Authors:  Michael A Nauck; Nele Friedrich
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.